Autism Research

Cover image for Vol. 10 Issue 5

Edited By: David G. Amaral, Ph.D

Online ISSN: 1939-3806



Author Guidelines


GUIDELINE SECTIONS

  1. Submission
  2. Aims and Scope
  3. Manuscript Categories and Requirements
  4. Preparing the Submission
  5. Editorial Policies and Ethical Considerations
  6. Author Licensing
  7. Publication Process After Acceptance
  8. Post Publication
  9. Journal Contact Details

1. SUBMISSION


Authors should note that submission implies that the content has not been published or submitted for publication elsewhere except possibly as a brief abstract in the proceedings of a scientific meeting or symposium. If there is a related paper under consideration at another journal, the corresponding author should inform the Editor in the cover letter and a copy of that paper should be submitted with the primary manuscript as supporting information.

Authors should follow the guidelines carefully; failure to do so will delay the processing of the manuscript. Once the submission materials have been prepared in accordance with the Author Guidelines, manuscripts should be submitted online at manuscriptcentral.com/autismresearch. Authors unfamiliar with ScholarOne can find details on how to use the system here: www.wileyauthors.com/scholarone.

The submission system will prompt authors to use an ORCID iD (a unique author identifier) to help distinguish their work from that of other researchers. Details can be found elsewhere in these guidelines.

For help with submissions, please contact the Editorial Office: autismres@wiley.com. When necessary, the Editorial Office staff may refer questions to the Editor-in-Chief or Associate Editors.

Return to the Table of Contents

2. AIMS AND SCOPE


Autism Research is owned and supported by The International Society for Autism Research (INSAR), a scientific and professional organization devoted to advancing knowledge about Autism Spectrum Disorder (ASD). For more information, please visit the Society Information section of the journal homepage.

Autism Research covers research relevant to ASD and closely related neurodevelopmental disorders. The journal focuses on genetic, neurobiological, immunological, epidemiological and psychological mechanisms and how these influence developmental processes in ASD. The journal encourages the submission of original research papers (Research Articles and Short Reports) that take a developmental approach to the biology and psychology of autism, with a particular emphasis on identifying underlying mechanisms and integrating across different levels of analysis. Contributions are typically empirical, but the journal also publishes theoretical papers if they significantly advance thinking. The journal encourages papers reporting work on animals or cell or other model systems that are directly relevant to a better understanding of ASD. The journal also publishes reports of carefully conducted clinical trials of treatments for the core symptoms or one of the common co-morbid symptoms of ASD. Papers presenting clinical trials will be judged, in part, on whether there is an empirical justification for the reported treatment. Individuals included in research studies can span the full spectrum of ASD, including the broader phenotype, and there are no restrictions on study participants in terms of age or intellectual ability.

Return to the Table of Contents

3. MANUSCRIPT CATEGORIES AND REQUIREMENTS


Autism Research publishes the following contribution types:

  1. Research Articles
  2. Short Reports
  3. Review Articles
  4. Commentaries
  5. Letter to the Editor

Manuscripts should be prepared according to the descriptions below. Submissions that do not conform to one of the descriptions below will be returned to the author.

1. Research Articles.

The text of these articles should include a scientific Abstract (150–250 words), a Lay Summary (see details elsewhere), and they should follow the IMRaD guidelines (Introduction, Methods, Results, and Discussion), which are recommended by the International Committee of Medical Journal Editors (ICMJE) (J. Pharmacol. Pharmacother. 2010, 1, 42–58). Manuscripts should be a maximum of 5,000 words in length (excluding Abstracts and References). If there are extenuating circumstances that require an increased length, authors should contact the Editorial Office with specific details and rationale for the Editor-in-Chief’s consideration.

2. Short Reports.

These are original research articles that report a well-conducted preliminary study or a novel finding of high potential impact. Typically these articles should not exceed 2,000 words in length (excluding Abstracts and References). The text of these articles should include a scientific Abstract (150–250 words), a Lay Summary (see details elsewhere), and while subsection headings are not specifically required, the flow of text should follow the IMRaD guidelines (Introduction, Methods, Results, and Discussion), which are recommended by the International Committee of Medical Journal Editors (ICMJE) (J. Pharmacol. Pharmacother. 2010, 1, 42–58).

3. Review Articles.

Review Articles are generally invited. However, authors are encouraged to contact the Editor-in-Chief if they are interested in preparing a Review on a timely topic that has not recently been covered by the journal. Permission of the Editor-in-Chief must be obtained prior to submission of a Review Article. Review Articles are typically up to 8,000 words in length (excluding Abstracts and References).

Review Articles should be accompanied by an Abstract of (150–250 words) and a Lay Summary (see details elsewhere). The manuscript can be organized as the authors wish, but should be logically structured to ensure readability.

4. Commentaries.

These are short articles (1500–3,000 words in length excluding Abstract and References) that are intended to 1) draw attention to developments or needs in a specific area of research, 2) bring together observations that point the field in a new direction, 3) give the authors’ personal views on a controversial topic, or 4) direct well-reasoned and substantive criticism of some widely held theoretical view or widely used technique or practice. Commentaries may also provide a historical perspective on an area of autism research. Authors should make their Commentary understandable to a broad readership. As with all other contribution types, they should have an Abstract of (150–250 words) and a Lay Summary (see details elsewhere).

Potential authors are invited to submit a letter of interest to the Editor-in-Chief indicating the topic of a potential Commentary. The letter should also contain an outline of the contents and a brief statement on why it is a good time to review the topic in question. Commentaries will not be accepted for editorial processing unless pre-approved for submission.

5. Letters to the Editor.

From time to time, readers respond to an article published in Autism Research by writing a Letter to the Editor. Such letters may further the scientific discussion and provide meaningful context to the published work. Letters to the Editor do not have either an Abstract or a Lay Summary; they only have a few citations (always less than five) and those should be limited to the article in question and highly relevant references in support of the discourse. These contributions should be short (usually 300 words or less). They should be written in continuous prose without subsections. Letters to the Editor are only published after full consultation with the Editor-in-Chief, and if necessary the authors and/or reviewers of the published contribution under discussion. Authors wishing to publish a Letter to the Editor should first contact the Editor-in-Chief via email (autismres@wiley.com), prior to formal submission of the manuscript, to ensure the intended manuscript meets the requirements of this contribution type.

Return to the Table of Contents

4. PREPARING THE SUBMISSION


Cover Letters

During the submission process, authors will have the opportunity to provide a cover letter directly in a text field of the submission questionnaire within ScholarOne. Therein, details of any invitation received, any information pertinent to the submission, etc. should be provided. Authors wishing to upload a separate cover letter together with the submission files may do so, though this is not required.

Parts of the Manuscript

The submission should be uploaded in separate files: 1) manuscript main text file; 2) figures; 3) Supporting Information file(s).

1. Manuscript Main Text File

The text file should contain all of the manuscript text, including the tables and figure legends. The text should be presented in the following order:

  1. Title
  2. A short running title of less than 40 characters
  3. The full names of all authors
  4. The authors' institutional affiliations where the work was conducted, with a footnote for an author’s present address if different to where the work was carried out
  5. Acknowledgments
  6. Lay Summary
  7. Abstract and Keywords
  8. Main text
  9. References
  10. Tables (each table complete with title and footnotes)
  11. Figure legends

Title

The title should be short and informative, containing major keywords related to the content. The title should not contain abbreviations (see Wiley's best practice SEO tips).

Authorship

For details on eligibility for author listing, please refer to the journal’s Authorship policy outlined in Section 5 of these Author Guidelines.

Acknowledgments

Contributions from individuals who do not meet the criteria for authorship should be listed, with permission from the contributor, in an Acknowledgments section. Financial and material support should also be mentioned. Thanks to anonymous reviewers are not appropriate.

Conflict of Interest Statement

Authors will be asked to provide a conflict of interest statement during the submission process. See the journal’s policy on Conflict of Interest outlined in Section 5 of these Author Guidelines. Authors should ensure they liaise with all co-authors to confirm agreement with the final statement.

Abstract

Please provide an abstract of 150–250 words containing the major keywords (see below). The abstract must be written in complete sentences. It should concisely state the questions addressed, the methods used, the main results and their significance. Importantly, the abstract should stand alone without references and with abbreviations appropriately defined. Note, the Abstract should not be structured; please do not include line breaks or paragraph headings.

Lay Summary

Autism Research and INSAR are committed to making scientific research accessible to both the scientific and non-scientific communities. In an effort to do this, since the journal’s launch, authors have provided lay summaries intended to inform the non-scientific community of important findings. In a continuing effort to refine this policy, each author is asked to provide an Lay Summary.

A brief statement of 2-3 sentences (60–80 words; 300–500 characters including spaces) included at the end of the Abstract that summarizes the impact/importance/relevance/key findings of the study. The Lay Summary should be aimed at interested persons without a scientific background.

Authors are encouraged to use a readability analyzer to evaluate the accessibility of their Lay Summary to non-scientists. Free online analyzers such as https://datayze.com/readability-analyzer.php provide an indication of the reading level of a given text.

An article’s Lay Summary appears immediately below the Abstract and appears together with the Abstract on Wiley Online Library, as well as in Abstract & Indexing services that cover the journal, such as PubMed. This ensures that the Lay Summary is available to any reader free of charge at the article level rather than the issue level.

Since its launch, Autism Research has sought to make scientific research accessible to non-scientists, particularly families with ASD. Like While the way in which the journal provides these lay abstracts has evolved over time, they are archived in a dedicated Special Features section of the journal’s website: www.autismresearchjournal.com.

Keywords

Please provide five to seven keywords. Keywords should be taken from those recommended by the US National Library of Medicine's Medical Subject Headings (MeSH) browser list at www.nlm.nih.gov/mesh.

Main Text

  • The text should be divided as outlined in Section 3 “Manuscript Categories and Requirements”.
  • Manuscripts reporting original research should follow the IMRaD guidelines (Introduction, Methods, Results, and Discussion), which are recommended by the International Committee of Medical Journal Editors (ICMJE) (J. Pharmacol. Pharmacother. 2010, 1, 42–58).
  • The journal uses US spelling. Authors may submit using any form of English as the spelling of accepted papers is converted to US English during the production process.
  • Footnotes to the text are not allowed and any such material should be incorporated into the text as parenthetical matter.
  • Authors for whom English is not their first language are encouraged to seek assistance from a native or fluent English speaker to proof read the manuscript prior to submission. Wiley offers a paid service that provides expert help in English language editing – further details are given below.
  • Articles reporting data taken from or deposited elsewhere should refer to the journal policy on Data Storage and Documentation in Section 5 (below).

References

Reference should be made only to articles that are published or in press. Unpublished results and personal communications should be cited parenthetically in the text, not in the reference list. Authors are responsible for the accuracy of the references.

References in the text should be made by author’s name followed by the year of publication, arranged chronologically, then alphabetically. When there are more than two authors, use the first author’s name and et al.

When references are made to more than one paper by the same author, published in the same year, designate them as a, b, c, etc. In the final list, arrange references alphabetically listing the first six authors, followed by et. al. where applicable, then year of publication. Spell out journal names in roman style, following these examples:

For Journals: Pinter, R., Hogge, W.A., & McPherson, E. (2004). Infant with severe penicillamine embryopathy born to a woman with Wilson disease. American Journal of Medical Genetics, Part A, 128A, 294–298.

Books: Reece, R.J. (2004). Analysis of genes and genomes. New York: Wiley-Liss. 469 p.

Chapter in Book: Hunter, A.G.W. (2005). Down syndrome. In: Cassidy, S.B., Allanson, J.E., editors. Management of genetic syndromes, 2e. New York: Wiley-Liss, pp 191–210.

Web Citation: U.S. Census Bureau. (2004). America's families and living arrangements: 2003 (Table C3). Retrieved November 24, 2004, from www.census.gov/population/www/socdemo/hh-fam/cps2003.html.

Tables

Each table must be numbered in order of appearance with Arabic numerals and be cited at an appropriate point in the text. Tables should be self-contained and complement, not duplicate, information contained in the text. They should be supplied as editable files (i.e., created in Microsoft Word or similar), not pasted as images. Legends should be concise but comprehensive—the table, legend, and footnotes must be understandable without reference to the text. All abbreviations must be defined in footnotes. Footnote symbols: †, ‡, §, ¶, should be used (in that order) and *, **, *** should be reserved for P-values. Statistical measures such as standard deviation (SD) or standard error of the mean (SEM) should be identified in the headings.

Figure Legends

Legends should be concise but comprehensive—the figure and its legend must be understandable without reference to the text. Include definitions of any symbols used and define/explain all abbreviations and units of measurement. Legends for each figure should not exceed 200 words.

2. Figures

Although authors are encouraged to send the highest quality figures possible, for peer-review purposes, a wide variety of formats, sizes, and resolutions are accepted. Click here for the basic figure requirements for figures submitted with manuscripts for initial peer review, as well as the more detailed post-acceptance figure requirements.

Helvetica typeface is preferred for lettering within figures. All letters, numbers and symbols must be at least 2 mm in height. Courier typeface should be used for sequence figures. Figures should be numbered consecutively with Arabic numerals, and they should be numbered in the order in which they appear in the text.

Figures should be submitted as electronic images to fit either one (55 mm, 2 3/16”, 13 picas), two (115 mm, 4 1/2”, 27 picas), or three (175 mm, 6 7/8”, 41 picas) columns. The length of an illustration cannot exceed 227 mm (9”). Journal quality reproduction requires grey scale and color files at resolutions of 300 dpi. Bitmapped line art should be submitted at resolutions of 600-1200 dpi.

Figures submitted in color will be reproduced in color online free of charge. Authors should note however, that it is preferable that line figures (e.g., graphs) are supplied in black and white so that they are legible if printed by a reader in black and white.

3. Supporting Information File(s)

Supporting information is information that is not essential to the article, but provides greater depth and background. If an article is accepted for publication, the Supporting Information is hosted online together with the article and appears without editing or typesetting. It may include, but is not limited to, video clips, large sections of tabular data, program code, or electronic graphical files that are otherwise not suitable inclusion in the main article. Click here for Wiley’s FAQs on Supporting Information.

Note: if data, scripts, or other artefacts used to generate the analyses presented in the paper are available via a publicly available data repository, authors should include a reference to the location of the material within their paper.

Supporting Information must be submitted at the time of peer review. The availability of this material should be indicated in the text of the article where appropriate.

Specific details:

A. For supplementary data other than simple image files

The data and a README file should be archived together using one of the popular archive protocols such as ZIP, TAR, GZIP, or SIT. If there is more than one piece of supplementary material, authors should submit a separate archive for each, with an accompanying README file. However, if it is intended that the multiple files be downloaded as a single unit by the end user, submit one archive and one README file.

B. Data file types.

There are no restrictions on file types of the data that may be submitted. However, authors should keep in mind that the more universal the file type the more accessible it is to the community. The use of popular compression protocols is highly encouraged. If the material is presented in PostScript format, it will be converted to an Adobe Acrobat PDF file.

C. Movies.

Movies should be submitted online in the following formats: QuickTime 7.0 or higher, .mpeg or .avi files. All movies should be submitted at the desired reproduction size and length. To avoid excessive delays in downloading the files, movies should be no more than 6 MB in size, and run between 30–60 seconds in length. Authors are encouraged to use QuickTime's "compress" option when preparing files to help control file size. Additionally, cropping frames and image sizes can significantly reduce file sizes. Files submitted can be looped to play more than once, provided file size does not become excessive. Authors will be notified if problems exist with videos as submitted, and will be asked to modify them. No editing will be done to the videos at the editorial office—all changes are the responsibility of the author.

General Style Points

The following points provide general advice on formatting and style.

  • Abbreviations: In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Initially, use the word in full, followed by the abbreviation in parentheses. Thereafter use the abbreviation only.
  • Units of measurement: Measurements should be given in SI or SI-derived units. Visit the Bureau International des Poids et Mesures (BIPM) website at www.bipm.fr for more information about SI units.
  • Numbers under 10 should be spelt out, except for: measurements with a unit (8 mmol/L); age (6 weeks old), or lists with other numbers (11 dogs, 9 cats, 4 gerbils).
  • Trade Names: Chemical substances should be referred to by the generic name only. Trade names should not be used. Drugs should be referred to by their generic names. If proprietary drugs have been used in the study, refer to these by their generic name, mentioning the proprietary name and the name and location of the manufacturer in parentheses.
  • Statistics: Authors should adhere to the journal’s policy on Sample Size when reporting studies.

Wiley Author Resources

Manuscript Preparation Tips: Wiley has a range of resources for authors preparing manuscripts for submission available here. In particular, authors may benefit from referring to Wiley’s best practice tips on Writing for Search Engine Optimization.

Editing, Translation, and Formatting Support: Wiley Editing Services can greatly improve the chances of a manuscript being accepted. Offering expert help in English language editing, translation, manuscript formatting, and figure preparation, Wiley Editing Services ensures that the manuscript is ready for submission.

Return to the Table of Contents

5. EDITORIAL POLICIES AND ETHICAL CONSIDERATIONS

Editorial Review and Acceptance

The acceptance criteria for all papers are the quality and originality of the research and its significance to journal readership. Except where otherwise stated, manuscripts are single-blind peer reviewed. Papers will only be sent to review if the Editor-in-Chief or Associate Editor determines that the paper meets the appropriate quality and relevance requirements. The Editors make every effort to provide an initial editorial decision within 30 days of submission.

Authors will usually be invited to revise their work before a final decision is taken. The revision step is key to maintaining the scientific standards of Autism Research, and the efforts of the Editors, Reviewers and Authors all contribute to the improvement of the manuscript and ultimately the journal. In order to ensure an efficient peer-review process and rapid publication of accepted papers, authors are asked to ensure that the revised manuscript is uploaded within 30 days (for minor revisions) or 60 days (for major revisions) of the initial decision date. If an author anticipates the need for a longer revision time, to avoid expiration of the invitation to revise, they should contact the Editor-in-Chief via the Editorial Office (autismres@wiley.com) well in advance of the due date.

Wiley's policy on confidentiality of the review process is available here: www.wileypeerreview.com/reviewpolicy.

Editorial Policy on Sample Size

It is increasingly clear that causal factors affecting ASD (e.g., genetic, environmental) are highly complex and that there are multiple etiologies of ASD, each possibly associated with different patterns of biological and behavioral features. In view of the known heterogeneity of ASD, adequate sample size is crucial. An adequate sample size may vary depending on the type of research that is conducted. The Journal encourages papers with larger sample sizes that use structured, research- based diagnostic instruments where ever possible and appropriate, in order to support the replicability of published results. When studies with modest samples are submitted, due to paradigm or other constraints, the journal encourages authors to discuss the research constraints that led to the smaller sample in appropriate parts of the text (i.e., Methods and Discussion sections). The journal also requests that authors briefly, but explicitly, discuss how the smaller sample size may limit the interpretation of research results as reliable estimates of the characteristics of the population of people affected by ASD. Reviewers will be instructed to take this issue into consideration when they judge the priority of a paper for publication.

Editorial Policy on Male and Female Subjects

There is increasing evidence that both the biological and behavioral features of autism spectrum disorder may be substantially different in male and female individuals. Therefore, authors are requested to justify the mixture of males and females in their study population and their decisions to pool across, and/or stratify by, sex in the analyses.

Editorial Policy on Studies involving Animals and Humans

Human Studies and Subjects
For manuscripts reporting studies that involve human participants, a statement identifying the ethics committee that approved the study and confirmation that the study conforms to recognized standards is required, for example: Declaration of Helsinki; US Federal Policy for the Protection of Human Subjects; or European Medicines Agency Guidelines for Good Clinical Practice.

Images and information from individual participants will only be published where the authors have obtained the individual's free prior informed consent. Authors do not need to provide a copy of the consent form to the publisher; however, in signing the author license to publish, authors are required to confirm that consent has been obtained. Wiley has a standard patient consent form available for use.

Authors must provide either of these two assurances: (1) a statement in the manuscript that the research was prospectively reviewed and approved by a duly constituted ethics committee (e.g., in the USA, the Institutional Review Board (IRB)or (2) a statement in the cover letter to the Editor-in-Chief that the manuscript is a retrospective case report that does not require ethics committee approval at that institution. Any other situations not covered by these two scenarios should be discussed with the Editor-in-Chief.

Clinical Trial Registration
The journal requires that clinical trials are prospectively registered in a publicly accessible database and clinical trial registration numbers are included in all papers that report their results. Authors are asked to include the name of the trial register and the clinical trial registration number at the end of the Abstract. If the trial is not registered, or was registered retrospectively, the reasons for this should be explained.

Animal Studies
A statement indicating that the protocol and procedures employed were ethically reviewed and approved, as well as the name of the Institutional Animal Care and Use Committee (IACUC)), must be included in the Methods section of the manuscript. Authors are encouraged to adhere to animal research reporting standards, for example the ARRIVE reporting guidelines for reporting study design and statistical analysis; experimental procedures; experimental animals and housing and husbandry. Authors should also state whether experiments were performed in accordance with relevant institutional and national guidelines for the care and use of laboratory animals:

Data Storage and Documentation

Autism Research encourages data sharing wherever possible, unless this is prevented by ethical, privacy, or confidentiality matters. Authors publishing in the journal are therefore encouraged to make their data, scripts, and other artefacts used to generate the analyses presented in the paper available via a publicly available data repository; however, this is not mandatory. If the study includes original data, at least one author must confirm that he or she had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Linking to Databases.

Authors generating genetic and protein sequence information should submit their data to the appropriate database listed elsewhere. Where third party data from a database is used in the study, appropriate citation to the relevant database should be given. Authors should ensure appropriate reference to the archived data. It is the responsibility of the author(s) to ensure that the database information that is provided with the manuscript is correct and up to date.

Sequence Data

Nucleotide sequence data can be submitted in electronic form to any of the three major collaborative databases: DDBJ, EMBL, or GenBank. It is only necessary to submit to one database as data are exchanged between DDBJ, EMBL, and GenBank on a daily basis. The suggested wording for referring to accession-number information is: ‘These sequence data have been submitted to the DDBJ/EMBL/GenBank databases under accession number U12345’. Addresses are as follows:

Proteins sequence data should be submitted to either of the following repositories.


Nomenclature

Species Names. Upon its first use in the title, abstract, and text, the common name of a species should be followed by the scientific name (genus, species, and authority) in parentheses. For well-known species, however, scientific names may be omitted from article titles. If no common name exists in English, only the scientific name should be used.

Genetic Nomenclature. Sequence variants should be described in the text and tables using both DNA and protein designations whenever appropriate. Sequence variant nomenclature must follow the current Human Genome Variation Society (HGVS) guidelines; see varnomen.hgvs.org, where examples of acceptable nomenclature are provided.

Research Reporting Guidelines

Accurate and complete reporting enables readers to fully appraise research, replicate it, and use it. Authors are encouraged to adhere to any research reporting standards relevant to their study. A list of the most well-known guidelines is given here:

Resource Identification Initiative

The journal supports the Resource Identification Initiative, which aims to promote research resource identification, discovery, and reuse. This initiative, led by the Neuroscience Information Framework and the Oregon Health & Science University Library, provides unique identifiers for antibodies, model organisms, cell lines, and tools including software and databases. These IDs, called Research Resource Identifiers (RRIDs), are machine-readable and can be used to search for all papers where a particular resource was used and to increase access to critical data to help researchers identify suitable reagents and tools.

Authors are asked to use RRIDs to cite the resources used in their research where applicable in the text, similar to a regular citation or Genbank Accession number. For antibodies, authors should include in the citation the vendor, catalogue number, and RRID both in the text upon first mention in the Methods section. For software tools and databases, please provide the name of the resource followed by the resource website, if available, and the RRID. For model organisms, the RRID alone is sufficient.

Additionally, authors must include the RIIDs in the list of keywords associated with the manuscript.

To Obtain Research Resource Identifiers (RRIDs):

  1. Use the Resource Identification Portal, created by the Resource Identification Initiative Working Group.
  2. Search for the research resource (please see the section titled “Search Features and Tips” for more information).
  3. Click on the “Cite This” button to obtain the citation and insert the citation into the manuscript text.

If there is a resource that is not found within the Portal, authors are asked to register the resource with the appropriate resource authority. Information on how to do this is provided in the “Resource Citation Guidelines” section of the Portal.

If any difficulties in obtaining identifiers arise, please contact rii-help@scicrunch.org for assistance.

Example Citations:

Antibodies: "Wnt3 was localized using a rabbit polyclonal antibody C64F2 against Wnt3 (Cell Signaling Technology, Cat# 2721S, RRID: AB_2215411)"

Model Organisms: "Experiments were conducted in c. elegans strain SP304 (RRID:CGC_SP304)"

Cell lines: "Experiments were conducted in PC12 CLS cells (CLS Cat# 500311/p701_PC-12, RRID:CVCL_0481)"

Tools, Software, and Databases: "Image analysis was conducted with CellProfiler Image Analysis Software, V2.0 (http://www.cellprofiler.org, RRID:nif-0000-00280)"

Ethical Considerations

Conflict of Interest

The journal requires that all authors disclose any potential sources of conflict of interest. Any interest or relationship, financial or otherwise that might be perceived as influencing an author's objectivity is considered a potential source of conflict of interest. These must be disclosed when directly relevant or directly related to the work that the authors describe in their manuscript.

Potential sources of conflict of interest include, but are not limited to: patent or stock ownership, membership of a company board of directors, membership of an advisory board or committee for a company, and consultancy for or receipt of speaker's fees from a company.

The existence of a conflict of interest does not preclude publication. It is the responsibility of the corresponding author to review this policy with all authors and collectively to disclose with the submission ALL pertinent commercial and other relationships. These conflicts of interest should be disclosed in the cover letter to the Editor-in-Chief, in the manuscript (under the Acknowledgment section), and in the online submission system. If the authors have no conflict(s) of interest to declare, they must also state this.

Funding Disclosure

Authors should list all funding sources in the Acknowledgments section. Authors are responsible for the accuracy of their funder designation. If in doubt, please check the Open Funder Registry for the correct nomenclature: www.crossref.org/services/funder-registry.

Authorship

The list of authors should accurately represent who contributed to the work and how. Qualification for authorship is based on the following criteria. All listed authors should:

  1. Have made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data;
  2. Been involved in drafting the manuscript or revising it critically for important intellectual content;
  3. Given final approval of the version to be published. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content; and
  4. Agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Contributions from anyone who does not meet the criteria for authorship should be listed, with permission from the contributor, in an Acknowledgments section (for example, to recognize contributions from people who provided technical help, collation of data, writing assistance, acquisition of funding, or a department chairperson who provided general support). Prior to submitting the article all authors should agree on the order in which their names will be listed in the manuscript.

Joint first or senior authorship: In the case of joint first authorship, a footnote should be added to the author listing, e.g. ‘X and Y should be considered joint first author’ or ‘X and Y should be considered joint senior author.’

ORCID

As part of the journal’s commitment to supporting authors at every step of the publishing process, the journal requires the submitting author (only) to provide an ORCID iD when submitting a manuscript. If the submitting author is not already registered with ORCID, they can do so here: orcid.org/register; this takes around 2 minutes to complete. For more information, visit www.wileyauthors.com/orcid.

Publication Ethics

This journal is a member of the Committee on Publication Ethics (COPE). Note this journal uses iThenticate’s CrossCheck software to detect instances of overlapping and similar text in submitted manuscripts. Read the Top 10 Publishing Ethics Tips for Authors at www.wileyauthors.com/ethics; a link to Wiley’s Publication Ethics Guidelines can also be found there.

Return to the Table of Contents

6. AUTHOR LICENSING


If a paper is accepted for publication, the author identified as the formal corresponding author will receive an email prompting them to log in to Author Services, where via the Wiley Author Licensing Service (WALS) they will be required to complete a copyright license agreement on behalf of all authors of the paper.

Authors may choose to publish under the terms of the journal’s standard copyright agreement, or OnlineOpen under the terms of a Creative Commons License.

General information regarding licensing and copyright is available here. To review the Creative Commons License options offered under OnlineOpen, please click here. (Note that certain funders mandate that a particular type of CC license has to be used; the Wiley Author Compliance Tool, available at www.wileyauthors.com/compliancetool, provides assistance to authors in checking for any open-access mandates from their funder(s).)

Self-Archiving Definitions and Policies

Note that the journal’s standard copyright agreement allows for self-archiving of different versions of the article under specific conditions. For more detailed information about self-archiving definitions and policies, visit www.wileyauthors.com/self-archiving.

Open Access

Authors choosing to publish their Autism Research article in an open-access format through the OnlineOpen service will be charged an Article Publication Charge (APC). A complete list of APCs for Wiley journals is available at www.wileyauthors.com/APCpricing.

For more information on Wiley’s compliance with the open-access policies of specific funders, visit www.wileyauthors.com/funderagreements.

Return to the Table of Contents

7. PUBLICATION PROCESS AFTER ACCEPTANCE


Accepted Articles Received in Production

Signing the License

When an accepted article is received by Wiley’s production team, the corresponding author will receive an email asking them to login or register with Wiley Author Services. The author will be asked to sign a publication license at this point. Further details are given in Section 6 of these Author Guidelines.

Proofs

Once the paper is typeset, the author will receive an email notification with the URL to download a PDF typeset page proof, as well as associated forms and full instructions on how to correct and return the file.

Please note that the author is responsible for all statements made in their work, including changes made during the editorial process—authors should check proofs carefully. Note that proofs should be returned within 48 hours from receipt.

Publication Charges

There are no charges associated with submitting to or publishing in Autism Research. The journal does offer an open-access option for which there is a charge, and further details are given elsewhere.

Early View

The journal offers rapid publication via Wiley’s Early View service. Early View (online Version of Record) articles are published on Wiley Online Library before inclusion in an issue. Note there may be a delay after corrections are received before the article appears online, as the proofs need to be reviewed and processed. Once the article is published on Early View, no further changes are possible. The Early View article is fully citable and carries an online publication date and Digital Object Identifier (DOI) for citations.

Return to the Table of Contents

8. POST PUBLICATION


Access and Sharing

When the article is published online:

  • The author receives an email alert (if requested).
  • The link to the published article can be shared through social media.
  • The author will have free access to the paper (after accepting the Terms & Conditions of use, they can view the article).
  • The corresponding author and co-authors can nominate up to ten colleagues to receive a publication alert and free online access to the article.

Authors may order print copies of the article. Instructions are sent at proofing stage. Alternatively, authors may use the following link: caesar.sheridan.com/reprints/redir.php?pub=10089&acro=aur or email chris.jones@sheridan.com.

Promoting an Article

Ideas and guidance for authors on how to promote their research are given here: www.wileyauthors.com/maximize.

Authors intending to issue a press release through their institution or affiliation are kindly asked to inform the Editorial Office at their earliest convenience.

Measuring the Impact of an Article

Wiley also helps our authors measure the impact of their research through specialist partnerships with Kudos and Altmetric.

Return to the Table of Contents

9. JOURNAL CONTACT DETAILS


Author queries regarding submissions under review or accepted articles in production should be directed to the Editorial Office (autismres@wiley.com) or Production Editor (aurprod@wiley.com), respectively. A complete list of contacts for Autism Research is available on the journal’s contacts page.

Return to the Table of Contents

 

Author Guidelines updated May 9, 2017

SEARCH

SEARCH BY CITATION